Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists

Yarbrough, George G.; McGuffin-Clineschmidt, Jodie C.; Singh, Dilip Kumar; Haubrich, Dean R.; Bendesky, Robert J.; Martin, Gregory E.

doi:10.1016/0014-2999(84)90433-3

Cited by 30 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1976;Strombom 1975Strombom , 1976Costall et al 1981). This behavioral measure correlates significantly to other in vitro and electrophysiological measures of autoreceptor activation Yarbrough et al 1984). Although individually housed mice had levels of activity higher than the group housed mice following saline or APO, APO produced significant reductions in motor activity in both grouped and individually housed mice.…”

Section: Discussionmentioning

confidence: 86%

Behavioral and biochemical studies of dopamine receptor sensitivity in differentially housed mice

VanderWende

1986

Psychopharmacology

View full text Add to dashboard Cite

Group housed and individually housed mice were compared in (1) the motor activity responses to direct and indirect dopamine (DA) agonists, (2) in vivo presynaptic autoreceptor sensitivity and (3) in vitro binding of 3H-spiperone. Relative to group housed mice, individually housed mice showed an increased motor activity response to amphetamine, 1.25 and 0.625 mg/kg. Using two in vivo measures of presynaptic DA receptor sensitivity, the antagonism of spontaneous locomotor activity and the antagonism of dihydroxyphenylalanine (DOPA) accumulation by apomorphine (APO), individually housed mice showed greater activity counts and higher DOPA accumulations than group housed mice. Levels of tyrosine were significantly greater in individually housed mice. Significant effects of housing were also noted with the motor activity response to APO, 0.075-0.300 mg/kg, following pretreatment with reserpine, an in vivo measure of postsynaptic receptor sensitivity. However, there was no effect of housing on the number or affinity of 3H-spiperone binding sites in the striatum. These results are discussed in terms of the presynaptic activity of catecholaminergic neurons and the postsynaptic receptor sensitivity to APO in individually housed mice.

show abstract

Section: Discussionmentioning

confidence: 86%

Behavioral and biochemical studies of dopamine receptor sensitivity in differentially housed mice

VanderWende

1986

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…These receptors have been characterized in the corpus striatum, the nucleus accumbens, the olfactory tubercle, the limbic system and the rostral part of the cerebral cortex of the rat (And+n et al 1983). Selective stimulation of D-2 autoreceptors inhibits DA synthesis and release and DA neuronal firing at central sites (Langer et al 1980;Yarbrough et al 1984;Trulson 1985). In agreement with these findings, doses of apomorphine, bromocriptine or pergolide which provoke hypomotility and sleep induce a fall in striatal DOPA and HVA levels (Baudry et al 1977;Di Chiara et al 1976;Sumners et al 1981;Fuller et al 1982;Jiang et al 1984).…”

Section: Discussionmentioning

confidence: 99%

Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat

et al. 1988

View full text Add to dashboard Cite

The effects of the dopamine (DA) receptor agonists apomorphine, bromocriptine and pergolide were compared with those produced by a DA receptor antagonist, haloperidol, in rats implanted with electrodes for chronic sleep recordings. Apomorphine (0.025-2.0 mg/kg) and bromocriptine (0.25-6.0 mg/kg) induced biphasic effects such that low doses decreased wakefulness (W) and increased slow wave sleep (SWS) and REM sleep (REMS), while large doses induced opposite effects. The effects of pergolide (0.05-0.5 mg/kg) on W and SWS were also biphasic, while REMS was suppressed over the range of dosages given. At 0.040 mg/kg, haloperidol increased W, while at 0.160 mg/kg it produced the opposite effect. Pretreatment with haloperidol (0.020 mg/kg) in a dose which preferentially acts at presynaptic sites reversed the effects of low doses of apomorphine, bromocriptine or pergolide on sleep and W. However, the compound differed substantially in its ability to block agonist effects. The increase in sleep after low doses of apomorphine, bromocriptine or pergolide could be related to activation of presynaptic D-2 receptors located on DA axons of mesolimbic and mesocortical systems. In addition, inhibition of norepinephrine and acetylcholine neurons having inhibitory D-2 receptors could contribute to the increase of sleep after small doses of the DA agonists.

show abstract

“…In support of this view, we recently found in in-vivo investigations, using [123I] labeled (S)-2-hydroxy-3-iodo-6-methoxy-([1-ethyl-2-pyrrolidinyl]methyl) benzamide (IBZM) (= p23I]IBZM, a highly selective CNS D2 dopamine receptor ligand) and single photon emission tomography (SPET) a reduced striatal D2 dopamine receptor density in NMS (Staedt et al, 1993(Staedt et al, , 1995b. Since D2 dopamine autoreceptors are involved in synthesis and release of dopamine (Brown et al, 1985;Yarbrough et al, 1984), the reduced D2 receptor density in RLS/NMS may reflect a diminished tonic dopaminergic level. To date, L-Dopa is the treatment of first choice in RLS and NMS.…”

Section: Introductionmentioning

confidence: 99%

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

Staedt

Wassmuth

Ziemann

et al. 1997

J. Neural Transmission

View full text Add to dashboard Cite

A double-blind randomized crossover study of 0.125 mg Pergolide (Lilly) at bedtime versus 250mg L-Dopa + Carbidopa (Roche) was conducted in 16-day phases in 11 patients with idiopathic restless legs syndrome. Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide. Only 1 patient experienced an improvement of restlessness after L-Dopa. The patients showed polysomnographically a mean decrease in NMS cluster disturbed time by 45% from control on L-Dopa (p < 0.025) and by 79% from control on Pergolide (p < 0.001). In addition, Pergolide increased the total sleep time compared to L-Dopa (p < 0.05). In conclusion, the dopamine agonist Pergolide is superior to L-Dopa in the treatment of RLS and NMS.

show abstract

Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists

Cited by 30 publications

References 12 publications

Behavioral and biochemical studies of dopamine receptor sensitivity in differentially housed mice

Behavioral and biochemical studies of dopamine receptor sensitivity in differentially housed mice

Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

Contact Info

Product

Resources

About